AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02259868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS /1B, current high dose formulation
Study NCT02259868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation
Study NCT02259868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation
Study NCT02259868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Suspension low dose
Study NCT02259868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Suspension high dose
Study NCT02259868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT00193128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
Study NCT00193128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
Study NCT00193128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
Study NCT00193128 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
Study NCT01601990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group(once daily)
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
Study NCT01601990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444 50mg qd
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
Study NCT03128255 — intervention group
Intervention type: OTHER
Intervention: Assessment of already preacquired I-124 PET/US
Description: Assessment of preacquired I-124 PET/US by review of anonymous digital case files
Study NCT03351062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day.
Study NCT03351062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Description: Patients will be given 60mg Toremifene once a day.
Study NCT04507516 — intervention group
Intervention type: OTHER
Intervention: Water-only Fasting
Description: Water-only fasting for at least 10 days followed by 5 days of refeed.
Study NCT03336281 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
Study NCT01454609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal saline
Description: Saline
Study NCT03583489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: 10 mg IV
Study NCT01454609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
Study NCT01454609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine (combination)
Description: Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg
Study NCT00296465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsatile gonadotropin-releasing hormone (GnRH)
Description: Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
Study NCT00296465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Oral clomiphene citrate (over encapsulated) for 5 days
Study NCT00296465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pulsatile GnRH
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
Study NCT00296465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pulsatile GnRH
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
Study NCT00296465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Clomiphene Citrate
Description: oral placebo clomiphene citrate for 5 days
Study NCT00296465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Clomiphene Citrate
Description: oral placebo clomiphene citrate for 5 days
Study NCT03960060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-59
Description: Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
Study NCT01624961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg +0.002 IU/kg/h
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg +0.004 IU/kg/h
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg +0.008 IU/kg/h
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg +0.002 IU/kg/h
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg +0.004 IU/kg/h
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
Study NCT04404790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg +0.008 IU/kg/h
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
Study NCT05223023 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training
Study NCT02570724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of HES  Voluven® 
Description: Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
Study NCT02570724 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood patch
Study NCT01523743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact
Description: The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
Study NCT01523743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The coated intermittent catheter normally used by subject
Study NCT01062724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primene 10 % from Baxter
Description: Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
Study NCT00956137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: ultrasound imaging
Study NCT00956137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual palpation
Description: Manual Palpation of vertebra
Study NCT01389453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cell transplantation
Description: Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
Study NCT00203918 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey, interview
Description: A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
Study NCT03583489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT03583489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 4 mg IV
Study NCT03490097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 10mg
Description: tablets
Study NCT03490097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir plus daclatasvir
Description: sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
Study NCT03490097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir plus daclatasvir
Description: sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
Study NCT02804932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g/day) for 8 weeks
Study NCT02804932 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Super Beets Placebo
Description: Nitrate deficient beetroot powder (10g/day) for 8 weeks
Study NCT01693653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: Intravenous infusions every 4 weeks for 3 doses.
Study NCT01693653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Intravenous infusions every 4 weeks for 3 doses.
Study NCT00203918 — intervention group
Intervention type: BEHAVIORAL
Intervention: patient utility scores (i.e. patient preference weights)
Description: comparison of patient preferences
Study NCT01878838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
Description: Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
Study NCT01878838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser
Description: Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
Study NCT02085317 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetylcholine Iontophoresis
Description: Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
Study NCT02085317 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sodium nitroprusside Iontophoresis
Description: After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
Study NCT04763304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gown personal protective equipment (PPE-G) suit
Description: Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
Study NCT04763304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coverall personal protective equipment (PPE-C) suit
Description: Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
Study NCT02758561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist.
Study NCT01942395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH/sodium-restricted diet (DASH/SRD)
Description: Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
Study NCT01526798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theralite (high cut-off hemodialysis)
Description: Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
Study NCT01526798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional high-flux dialyzer
Study NCT00599924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
Study NCT00599924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
Study NCT00599924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
Study NCT00599924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
Study NCT00599924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
Study NCT00599924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
Study NCT00599924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFOX
Description: 25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
Study NCT02936570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)
Study NCT04773483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quorn Foods products
Description: 180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
Study NCT04773483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meat/fish products
Description: Standard meat/fish products matched to Quorn group for protein intake
Study NCT01942395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
Study NCT04591704 — intervention group
Intervention type: OTHER
Intervention: hospitalisation, necessity of ICU, mortality rate, lung involvement
Description: hospitalisation, necessity of ICU, mortality rate, lung involvement
Study NCT02255604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
Description: 4
Study NCT02255604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
Description: 3 injection into a lymphnode
Study NCT02255604 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.1 ml Isoton saline
Description: 4 injection into a lymphnode
Study NCT02534870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet
Study NCT02534870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet
Study NCT02638545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
Study NCT05954013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PD_Pal intervention
Description: The PD_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD_Pal intervention, i.e. the PD_Pal nurse. In the PD_Pal intervention, the patient, family caregiver and PD_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD_Pal nurse.
Study NCT03808545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)
Description: This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.